Company / Capital Expenditures
Esperion Therapeutics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2025
5-year range
$0 / $317.0K
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
#190 of 194
Health Care
What the data says
Remained stable around $0 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 194
▼
Key checks
Key Insights
- In FY2025, capital expenditures decreased 100.0% year-over-year.
- Peak capital expenditures was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $317.0K | - |
| FY2023 | $0 | - |
| FY2022 | $0 | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $869.0K | -8.8% |
| FY2019 | $953.0K | +531.1% |
| FY2018 | $151.0K | +694.7% |
| FY2017 | $19.0K | -79.8% |
| FY2016 | $94.0K | -71.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026